Bank OF Ceylon Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: Bank OF Ceylon Pharmaceutical Import Records from India — 6 Products, $409.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bank OF Ceylon — Pharmaceutical Importer Profile (2026) | 6 Products, $409.8K Trade | TransData Nexus

Bank OF Ceylon

Pharmaceutical Importer · Sri Lanka · Advanced Antibiotics Focus · $409.8K Total Trade · DGFT Verified

Bank OF Ceylon is a pharmaceutical importer based in Sri Lanka with a total trade value of $409.8K across 6 products in 3 therapeutic categories. Based on 16 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Bank OF Ceylon sources from 64 verified Indian suppliers, with United Biotech Private Limited accounting for 14.1% of imports.

Bank OF Ceylon — Import Portfolio & Supplier Network

Bank OF Ceylon import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Bank OF Ceylon?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
United Biotech Private Limited	$2.1M	210	14.1%
Torrent Pharmaceuticals Limited	$1.5M	51	9.7%
Bharat Serums And Vaccines Limited

What Formulations Does Bank OF Ceylon Import?

Formulation	Value	Ships
Amphonex 50MG (lyophilized) [liposomal	$350.0K	7
Cephalexin oral suspension BP 125MG/5ML	$300.0K	6
Pharmaceutical products, prednisolone syrup 5 MG/ 5 ML (pred-kid syrup 60 ML) Each 5 ML (approx.1 teaspoonful)	$186.3K	6
Human medicine-sodium chloride	$168.5K	6
Dilzem sr tablet(diltiazem	$150.0K	3
Mosid mt 5 tablet(mosapride citrate 5MG)	$150.0K	3
Thymogam 250MG [antithymocyte globulin	$149.5K	3
Pharma product:fepadol 500	$140.6K	10
Ceftil 500cefuroxime axetil USP 500MG	$111.7K	3
(single vaccines for tetanus) tetanus vaccine 1 dose vaccine for human	$103.5K	6
Allopurinol tablets USP 100MG (hilric)	$102.5K	4
Paracetamol tablets BP 500MG	$100.0K	2
Everolimus tablets 0.25MG Each	$100.0K	2
Calcium polystyrene sulphonate powder	$100.0K	2
Rhoclone 300 MCG lyophilized anti rho d injection immunoglobulin	$100.0K	2

Bank OF Ceylon imports 673 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Teicoplanin	Advanced Antibiotics	$113.2K	4	1.8%	11
2	Imipenem	Advanced Antibiotics	$100.0K	2	0.3%	6
3	Insulin	Diabetes & Endocrine	$100.0K	2	0.1%	14
4	Ifosfamide	Advanced Oncology	$62.5K	3	2.6%	7
5	Dacarbazine	Advanced Oncology	$23.0K	3	1.6%	9
6	Daunorubicin	Advanced Oncology	$11.1K	2	1.6%	8

Bank OF Ceylon imports 6 pharmaceutical products across 3 categories into Sri Lanka totaling $409.8K.

Bank OF Ceylon — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Bank of Ceylon (BOC), established in 1939, is a state-owned commercial bank headquartered in Colombo, Sri Lanka. As the largest bank in the country, BOC offers a comprehensive range of financial services, including retail and corporate banking, trade finance, and foreign exchange services. In addition to its core banking operations, BOC plays a pivotal role in facilitating the importation of essential goods, notably pharmaceuticals, to ensure the continuous availability of critical medical supplies within Sri Lanka. The bank's involvement in pharmaceutical imports underscores its commitment to supporting the nation's healthcare infrastructure and addressing public health needs.

2Distribution Network

BOC's distribution network for pharmaceutical imports is strategically designed to ensure efficient delivery across Sri Lanka. While specific warehouse locations are not publicly disclosed, the bank's extensive branch network and logistical capabilities enable it to coordinate the importation and distribution of pharmaceutical products nationwide. This infrastructure ensures that essential medicines reach various regions promptly, supporting the healthcare system's responsiveness and effectiveness.

3Industry Role

In Sri Lanka's pharmaceutical supply chain, BOC functions primarily as a financial intermediary facilitating the importation of pharmaceutical products. The bank's role involves providing the necessary financial services, such as opening Letters of Credit (LCs), to enable importers to procure medicines from international suppliers. By offering these trade finance services, BOC ensures that pharmaceutical products are imported efficiently, contributing to the stability and reliability of the country's pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Bank OF Ceylon

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

BOC's pharmaceutical import activities are characterized by a high degree of concentration among a limited number of Indian suppliers. The top five products imported—Teicoplanin, Imipenem, Insulin, Ifosfamide, and Dacarbazine—account for 97.3% of the total import value. This concentration suggests a strategic choice to source specific, high-demand medicines from established suppliers, potentially ensuring consistent quality and supply. However, such dependency also poses risks, including supply chain disruptions if any of these suppliers face operational challenges. The stability of these relationships is crucial for maintaining uninterrupted access to essential pharmaceuticals.

2Supply Chain Resilience

The resilience of BOC's pharmaceutical supply chain is closely tied to the stability and reliability of its Indian suppliers. The bank's focus on a select group of suppliers may streamline procurement processes but also increases vulnerability to disruptions from these sources. To enhance supply chain resilience, BOC could consider diversifying its supplier base and establishing relationships with alternative suppliers. Additionally, ensuring that all suppliers adhere to Good Manufacturing Practices (GMP) recognized by the World Health Organization (WHO) is essential for maintaining product quality and compliance with international standards.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. Established under the NMRA Act No. 5 of 2015, the authority is responsible for ensuring the safety, efficacy, and quality of medicines available in the country. Key legislation governing pharmaceutical imports includes the Medicines (Pricing Mechanism for Medicines) Regulations, which establish a standardized pricing formula for imported medicines. The marketing authorization pathway for Indian generics involves obtaining approval from the NMRA, which includes submitting comprehensive documentation and undergoing inspections to verify compliance with regulatory standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Sri Lanka are stringent. All pharmaceutical products must be registered with the NMRA before importation, and import license applications should be submitted at least twelve weeks in advance to avoid delays. As of February 2026, the NMRA has introduced new requirements for price submissions, particularly for import licenses that expire on or after 1st February 2026. Good Manufacturing Practice (GMP) certificates recognized by the World Health Organization (WHO) are mandatory for foreign manufacturers seeking to export to Sri Lanka. Additionally, importers must obtain a wholesale distribution authorization from the NMRA to legally distribute pharmaceutical products within the country.

Bank OF Ceylon — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

BOC's focus on importing specific therapeutic areas—Advanced Antibiotics, Diabetes & Endocrine, and Advanced Oncology—aligns with the critical healthcare needs of the Sri Lankan population. The demand for these products is driven by the prevalence of infectious diseases, diabetes, and cancer within the country. By concentrating on these areas, BOC ensures the availability of essential medicines that address significant public health concerns, thereby supporting the overall health infrastructure and improving patient outcomes.

2Sourcing Profile

BOC's sourcing strategy emphasizes the importation of generic drugs, particularly in the therapeutic areas of Advanced Antibiotics, Diabetes & Endocrine, and Advanced Oncology. The bank's procurement focuses on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. India plays a pivotal role in BOC's overall procurement strategy, serving as the primary source for these essential medicines due to its established pharmaceutical manufacturing capabilities and the availability of WHO-recognized GMP-certified products.

3Market Positioning

Seller's Guide — How to Become a Supplier to Bank OF Ceylon

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter BOC's sourcing network, particularly if they can offer high-quality generic drugs in the therapeutic areas of Advanced Antibiotics, Diabetes & Endocrine, and Advanced Oncology. Gaps in BOC's current sourcing may include a limited supplier base and potential vulnerabilities associated with supplier concentration. New suppliers can address these gaps by providing alternative sources for essential medicines, thereby enhancing supply chain resilience and offering competitive pricing.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to BOC and the Sri Lankan market must obtain GMP certificates recognized by the WHO. Additionally, they must ensure that their products are registered with the NMRA and comply with all relevant import licensing requirements. Adherence to Sri Lankan labeling standards, including bilingual labeling in English and Sinhala, is mandatory. Exporters should also be prepared to provide batch release certificates and material safety data sheets (MSDS) to verify product quality and safety.

3How to Approach

Frequently Asked Questions — Bank OF Ceylon

What products does Bank OF Ceylon import from India?

Bank OF Ceylon imports 6 pharmaceutical products across 3 categories. Top imports: Teicoplanin ($113.2K), Imipenem ($100.0K), Insulin ($100.0K), Ifosfamide ($62.5K), Dacarbazine ($23.0K).

Who supplies pharmaceuticals to Bank OF Ceylon from India?

Bank OF Ceylon sources from 64 verified Indian suppliers. The primary supplier is United Biotech Private Limited (14.1% of imports, $2.1M).

What is Bank OF Ceylon's total pharmaceutical import value?

Bank OF Ceylon's total pharmaceutical import value from India is $409.8K, based on 16 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Bank OF Ceylon focus on?

Bank OF Ceylon imports across 3 categories. The largest: Advanced Antibiotics (52.0%), Diabetes & Endocrine (24.4%), Advanced Oncology (23.6%).

Get Full Bank OF Ceylon Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.